Company intelligence / Profile preview

Felderson

Quebec City, Quebec, Canadafeldersontowingllc.com ↗

Ownership: Private
Development stage: Other

Overview

Feldan Therapeutics is a clinical-stage biotech company pioneering the development of therapies based on its proprietary peptide-based intracellular delivery platform, the Feldan Shuttle. Its lead candidate FLD-103 is in Phase 1/2a trials for basal cell carcinoma as a non-surgical alternative to current treatments. Early data focus on safety, tolerability, and preliminary efficacy; additional programs are in preclinical or discontinued stages.

Therapeutic areas: Oncology
Modalities: PeptidesSmall moleculeBiologicCell therapy
Industry: Biotech

Partnerships

Genesys Capital [investor and strategic partner]Fonds de solidarité FTQ [investor and strategic partner]Linearis Ventures [strategic investor with oncology expertise]Amgen [shareholder/investor support noted in recent funding round ]

Beyond the preview

Go deeper on Felderson.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Felderson.

Explore the full profile